Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
Top Cited Papers
Open Access
- 19 December 2012
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 308 (23) , 2497-2506
- https://doi.org/10.1001/jama.2012.25790
Abstract
Reduction of low-density lipoprotein cholesterol (LDL-C) is the cornerstone of cardiovascular risk reduction,1-3 with specific LDL-C goals based on cardiovascular outcome trials.1-4 Statins are currently the most effective agents for reducing LDL-C levels.5 However, of approximately 20 million patients treated with statins,6 an estimated 10% to 20% are unable to tolerate any statins or the higher doses necessary to achieve current LDL-C goals, primarily because of muscle-related side effects.7Keywords
This publication has 12 references indexed in Scilit:
- Faculty Opinions recommendation of ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Published by H1 Connect ,2014
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol LevelsJournal of the American College of Cardiology, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJournal of the American College of Cardiology, 2012
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialThe Lancet, 2012
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trialEuropean Heart Journal, 2012
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Effects of the Prosegment and pH on the Activity of PCSK9Journal of Biological Chemistry, 2010
- Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)The American Journal of Cardiology, 2007
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005